1-7 of 7
Xiuning Le
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

Available to Purchase
Natalie I. Vokes, Xiuning Le, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3968–3970.
https://doi.org/10.1158/1078-0432.CCR-24-1188
Published: 13 September 2024
View articletitled, PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC
Open the PDF for PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC in another window
Journal Articles

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC

Open Access
Natalie I. Vokes, Ana Galan Cobo, Margarita Fernandez-Chas, David Molkentine, Santiago Treviño, III, Vitaly Druker, Yu Qian, Sonia Patel, Stephanie Schmidt, Lingzhi Hong, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, J. Jack Lee, Marcelo V. Negrao, Don L. Gibbons, Ara Vaporciyan, Xiuning Le, Jia Wu, Jianjun Zhang, Una Rigney, Sonia Iyer, Emma Dean, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4958–4972.
https://doi.org/10.1158/1078-0432.CCR-23-1122
Published: 01 December 2023
View articletitled, ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Open the PDF for ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC in another window
Includes: Supplementary data
Journal Articles

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Available to Purchase
Sonia A. Patel, Monique B. Nilsson, Yan Yang, Xiuning Le, Hai T. Tran, Yasir Y. Elamin, Xiaoxing Yu, Fahao Zhang, Alissa Poteete, Xiaoyang Ren, Li Shen, Jing Wang, Seyed Javad Moghaddam, Tina Cascone, Michael Curran, Don L. Gibbons, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1292–1304.
https://doi.org/10.1158/1078-0432.CCR-22-3379
Published: 03 April 2023
View articletitled, IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Open the PDF for IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

Available to Purchase
Sonia A. Patel, Monique B. Nilsson, Xiuning Le, Tina Cascone, Rakesh K. Jain, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 30–39.
https://doi.org/10.1158/1078-0432.CCR-22-1366
Published: 04 January 2023
View articletitled, Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Open the PDF for Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy in another window
Journal Articles

Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection

Available to Purchase
Xiuning Le, Frederico O. Gleber-Netto, M. Laura Rubin, Yun Qing, Robyn Du, Merrill Kies, George Blumenschein, Jr, Charles Lu, Faye M. Johnson, Diana Bell, Jeff Lewis, Jiexin Zhang, Lei Feng, Kaye Wilson, Kathrina Marcelo-Lewis, Jing Wang, Lawrence Ginsberg, Maura Gillison, J. Jack Lee, Funda Meric-Berstam, Gordon B. Mills, William N. William, Jr, Jeffrey N. Myers, Curtis R. Pickering
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2796–2806.
https://doi.org/10.1158/1078-0432.CCR-21-3239
Published: 01 July 2022
View articletitled, Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Open the PDF for Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection in another window
Includes: Supplementary data
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Open Access
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View articletitled, Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

Free
Xiuning Le, Sonam Puri, Marcelo V. Negrao, Monique B. Nilsson, Jacqulyne Robichaux, Theresa Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Elamin, Lara C. Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William, Jr, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6195–6203.
https://doi.org/10.1158/1078-0432.CCR-18-1542
Published: 13 December 2018
View articletitled, Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Open the PDF for Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC in another window
Includes: Supplementary data